May 26, 2017/Cancer/News & Insight

ASCO 2017 – Monday, June 5

Please join our staff as we participate or present in the following oral and poster presentations at the 2017 ASCO Annual Meeting

#ASCO_650x450

Monday, June 5

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

7:30 AM – 9:15 AM
Location: Hall D1

HIGHLIGHTS OF THE DAY SESSION: Highlights of the Day Session II

7:30 AM – 7:50 AM
Central Nervous System Tumors
David M. Peereboom, MD – Discussant

8:00 AM – 9:15 AM
Location: S406

EDUCATION SESSION: Pancreatic Adenocarcinoma: Improving Prevention and Survivorship
Davendra Sohal, MD, MPH – Chair

8:00 AM – 8:20 AM
Best Practices in Management of Resectable Pancreatic Cancer: Emerging Standards for Adjuvant Therapy and Surveillance
Davendra Sohal, MD, MPH – Chair

8:00 AM – 9:15 AM
Location: E253cd

Advertisement

MEET THE PROFESSOR SESSION: Brain Metastases: Utilizing Genomics and Combining Treatment Modalities

8:00 AM – 8:20 AM
Innovative Targeted Therapeutic Approaches in Brain Metastases
Manmeet Singh Ahluwalia, MD – Speaker

8:00 AM – 11:30 AM
Location: Hall A

POSTER SESSION: Hematologic Malignancies — Leukemia, Myelodysplastic Syndromes, and Allotransplant
Abstract 7061: Phase I/II trial of glasdegib in patients with primary or secondary myelofibrosis
Poster Board: #261
Aaron Thomas Gerds, MS, MD – First Author

1:15 PM – 4:45 PM
Location: Hall A

POSTER SESSION: Central Nervous System Tumors
Abstract 2071: What drives patient outcomes in brain metastases: Number, volume, or biology?
Poster Board: #313
Rupesh Kotecha, MD – First Author

POSTER SESSION: Genitourinary (Prostate) Cancer
Abstract 5041: Clinical activity and safety of ASN001, a selective CYP17 lyase inhibitor, administered without prednisone in men with metastatic castration-resistant prostate cancer (mCRPC): A phase 1/2 clinical trial
Poster Board: #115
Jorge A. Garcia, MD – First Author

Advertisement

POSTER SESSION: Head and Neck Cancer
Abstract 6072: Prognostic factors associated with benefit to post-operative chemotherapy: A National Cancer Data Base analysis
Poster Board: #60
Jessica Lyn Geiger, MD – First Author

POSTER SESSION: Health Services Research, Clinical Informatics, and Quality of Care
Abstract 6557: Increase in time to initiating cancer therapy and association with worsened survival in curative settings: A U.S. analysis of common solid tumors
Poster Board: #379
Alok A. Khorana, MD – First Author

Abstract 6558: Minority patient reported attitudes regarding tissue donation and participation in cancer research
Poster Board: #380
Davendra Sohal, MD, MPH – First Author

Related Articles

adverse events from immune checkpoint inhibitors
December 21, 2023/Cancer/News & Insight
Managing Hormone Dysfunction-Related Adverse Events of Immunotherapy for Breast Cancer Treatment

Timing and type of side effects differ greatly from chemotherapy

23-CNR-4274330-CQD-Hero-650×450
October 18, 2023/Cancer/News & Insight
Cleveland Clinic Lerner Research Institute to Host Head & Neck Cancer CME Symposium

Sessions explore treatment advances and multidisciplinary care

23-CNR-4210971-CQD-Hero-650×450 Dr Yu
October 9, 2023/Cancer/News & Insight
Pathway Cross-Talk Suggests New Approach to Glioblastoma Treatment

New research from Cleveland Clinic helps explain why these tumors are so refractory to treatment, and suggests new therapeutic avenues

23-CNR-4071967-CQD-Hero-650×450 scan for triple-negative breast cancer case study
September 19, 2023/Cancer/News & Insight
Patient With Stage 4 Triple-Negative Breast Cancer in Remission 10 Years After Initial Diagnosis

Combination of olaparib and carboplatin results in complete durable response for a patient with BRCA2 and “BRCAness” mutations

23-CNR-4140381-CQD-Hero-650×450 eye toxicities in cancer treatment
September 7, 2023/Cancer/News & Insight
Eye Toxicities More Prevalent Side Effect of Cancer Treatment Than Previously Understood

Early communication between oncologists and ophthalmologist warranted

23-CNR-4185077-CQD-Hero-650×450
August 31, 2023/Cancer/News & Insight
CME Program Takes Multidisciplinary Approach to Colorectal Cancer

Case-based course delves into latest treatment approaches

outreach to underserved communities
June 2, 2023/Cancer/News & Insight
Focus Groups Amplify the Voices of Black Congregants about Disparities in Clinical Trials

Long-term relationship building and engagement key to gaining community trust

Ad